新诺威拟与中奇制药设立合资公司，主要聚焦于GLP-1靶点等相关产品

Core Viewpoint - The announcement reveals that XinNuoWei plans to establish a joint venture with Zhongqi Pharmaceutical, focusing on the development and commercialization of innovative metabolic drugs, particularly targeting GLP-1 related products [1] Group 1: Joint Venture Details - XinNuoWei will invest 157.5 million yuan, holding a 35% stake in the joint venture, while Zhongqi Pharmaceutical will contribute 292.5 million yuan for a 65% stake [1] - The total investment for the joint venture is set at 450 million yuan [1] Group 2: Business Focus - The joint venture will primarily focus on the research, industrialization, and commercialization of innovative metabolic drugs, targeting areas such as overweight/obesity and type 2 diabetes [1] - The company plans to develop new drug formulations and expand indications continuously [1] Group 3: Product Pipeline - The joint venture will take over all GLP-1 related product pipelines from Shijiazhuang Pharmaceutical Group, including those in preclinical research, clinical stages, and those submitted for market approval [1] - The company aims to enhance its product matrix through various methods, including independent development, rights acquisition, and pipeline introduction [1]